This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Neuromyelitis optica (NMO)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Neuromyelitis optica is a subacute demyelinating disease affecting the optic nerves and spinal cord. Bilateral optic neuritis and a spinal cord lesion present within the space of two to three months, with a variable subsequent course (1)

  • became known as Devic disease following a seminal 1894 report
  • Neuromyelitis optica was considered a monophasic disorder consisting of simultaneous bilateral optic neuritis and transverse myelitis
    • however relapsing cases were described in the 20th century

Neuromyelitis optica (NMO) is distinct from multiple sclerosis (MS) and is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) (2)

  • approximately 75% of patients have serum aquaporin-4 immunoglobulin G antibodies (3)
  • nomenclature defines the unifying term NMO spectrum disorders (NMOSD)

Epidemiology:

  • reported incidence and prevalence of NMOSD are dependent on geographical location and ethnicity
    • Asians and those of African ancestry are at increased risk, with high mortality rates reported in the latter (3)
    • incidence and prevalence of NMOSD ranges from 0.05-0.40 and 0.52-4.4 per 100,000 people respectively (3)

Diagnosis of neuromyelitis optica should be made by an appropriate specialist based on established up-to-date criteria (1).

  • NMOSD is stratified further by serologic testing (NMOSD with or without AQP4-IgG)
    • core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations
    • more stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable

Untreated, approximately 50% of NMOSD patients will be wheelchair users and blind, and a third will have died within 5 years of their first attack (3)

Unlike multiple sclerosis, a progressive clinical course is very unusual and the accrual of disability is related to relapses.

Management (3):

  • relapses are treated aggressively to prevent residual disability with high-dose steroids and often plasma exchange
  • relapse prevention is achieved with long-term immunosuppression.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.